Shares of ReShape Lifesciences Inc. (RSLS) are down over 55% at $0.71 in premarket trading today after an eye-popping 340% surge yesterday.
In an SEC filing yesterday, ReShape Lifesciences announced that it is unable to file its Form 10-K for the year ended December 31, 2024, on time without unreasonable effort or cost, as it requires additional time to complete the compilation of information. The company expects to file the Form 10-K within the extended period allowed by Rule 12b-25 of the Securities Exchange Act of 1934, which provides an additional 15 calendar days to submit a late 10-K.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com